{"transactions":[{"id":2104880,"issuer":{"id":122080,"kind":"organization","name":"Frazier Lifesciences Acquisition Corp","symbol":"FLAC"},"owners":[{"id":122085,"kind":"person","name":"Polu Krishna R","position":1,"cik":"0001630996","reported_name":"Polu Krishna R","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2022-11-23T16:25:50.000Z","date":"2022-11-22","kind":"exercise","acquired":false,"shares":30000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol \"NAMS\"). The Business Combination closed on November 22, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol \"NAMS\"). The Business Combination closed on November 22, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol \"NAMS\"). The Business Combination closed on November 22, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol \"NAMS\"). The Business Combination closed on November 22, 2022."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0000899243-22-036925","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630996/000089924322036925/doc4.xml","form_type":"4"}},{"id":3169931,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":122085,"kind":"person","name":"Polu Krishna R","position":1,"cik":"0001630996","reported_name":"Polu Krishna R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-04-24T17:31:58.000Z","date":"2020-04-22","kind":"grant","acquired":true,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on December 10, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020.  All of the other terms of the option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years."}],"balance_after":125000,"derivative":{"exercise_price":2.45,"expiration_date":"2029-12-09","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-20-025656","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1630996/000120919120025656/doc4.xml","form_type":"4"}},{"id":3169930,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":122085,"kind":"person","name":"Polu Krishna R","position":1,"cik":"0001630996","reported_name":"Polu Krishna R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-04-24T17:31:58.000Z","date":"2020-04-22","kind":"disposition_to_issuer","acquired":false,"shares":125000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on December 10, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020.  All of the other terms of the option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years."}],"balance_after":0,"derivative":{"exercise_price":4.75,"expiration_date":"2029-12-09","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-20-025656","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1630996/000120919120025656/doc4.xml","form_type":"4"}},{"id":3169929,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":122085,"kind":"person","name":"Polu Krishna R","position":1,"cik":"0001630996","reported_name":"Polu Krishna R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-04-24T17:31:58.000Z","date":"2020-04-22","kind":"grant","acquired":true,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on February 13, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020.  All of the other terms of the option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years."}],"balance_after":90000,"derivative":{"exercise_price":2.45,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-20-025656","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1630996/000120919120025656/doc4.xml","form_type":"4"}},{"id":3169928,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":122085,"kind":"person","name":"Polu Krishna R","position":1,"cik":"0001630996","reported_name":"Polu Krishna R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-04-24T17:31:58.000Z","date":"2020-04-22","kind":"disposition_to_issuer","acquired":false,"shares":90000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on February 13, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020.  All of the other terms of the option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years."}],"balance_after":0,"derivative":{"exercise_price":7.16,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-20-025656","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1630996/000120919120025656/doc4.xml","form_type":"4"}},{"id":3169927,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":122085,"kind":"person","name":"Polu Krishna R","position":1,"cik":"0001630996","reported_name":"Polu Krishna R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-04-24T17:31:58.000Z","date":"2020-04-22","kind":"grant","acquired":true,"shares":208216,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on August 16, 2018, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020.  All of the other terms of the option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years."}],"balance_after":208216,"derivative":{"exercise_price":2.45,"expiration_date":"2028-08-15","underlying":"Common Stock","underlying_shares":208216},"source":{"system":"sec-edgar","filing":"0001209191-20-025656","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1630996/000120919120025656/doc4.xml","form_type":"4"}},{"id":3169926,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":122085,"kind":"person","name":"Polu Krishna R","position":1,"cik":"0001630996","reported_name":"Polu Krishna R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-04-24T17:31:58.000Z","date":"2020-04-22","kind":"disposition_to_issuer","acquired":false,"shares":208216,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on August 16, 2018, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020.  All of the other terms of the option remained unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years."}],"balance_after":0,"derivative":{"exercise_price":3.3,"expiration_date":"2028-08-15","underlying":"Common Stock","underlying_shares":208216},"source":{"system":"sec-edgar","filing":"0001209191-20-025656","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630996/000120919120025656/doc4.xml","form_type":"4"}},{"id":3343356,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":122085,"kind":"person","name":"Polu Krishna R","position":1,"cik":"0001630996","reported_name":"Polu Krishna R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-12-12T17:54:07.000Z","date":"2019-12-10","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years."}],"balance_after":125000,"derivative":{"exercise_price":4.75,"expiration_date":"2029-12-09","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001209191-19-060268","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630996/000120919119060268/doc4.xml","form_type":"4"}},{"id":3653112,"issuer":{"id":6560,"kind":"organization","name":"Equillium, Inc."},"owners":[{"id":122085,"kind":"person","name":"Polu Krishna R","position":1,"cik":"0001630996","reported_name":"Polu Krishna R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-15T18:21:09.000Z","date":"2019-02-13","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years."}],"balance_after":90000,"derivative":{"exercise_price":7.16,"expiration_date":"2029-02-12","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-19-010766","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1630996/000120919119010766/doc4.xml","form_type":"4"}},{"id":4574208,"issuer":{"id":181476,"kind":"organization","name":"Raptor Pharmaceutical Corp","symbol":"RPTP"},"owners":[{"id":122085,"kind":"person","name":"Polu Krishna R","position":1,"cik":"0001630996","reported_name":"Polu Krishna R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option(right to buy)","published_at":"2016-10-26T16:35:51.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":89152,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":3.74,"expiration_date":"2026-02-09","underlying":"Common Stock","underlying_shares":89152},"source":{"system":"sec-edgar","filing":"0001140361-16-083643","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1070698/000114036116083643/doc1.xml","form_type":"4"}},{"id":4574207,"issuer":{"id":181476,"kind":"organization","name":"Raptor Pharmaceutical Corp","symbol":"RPTP"},"owners":[{"id":122085,"kind":"person","name":"Polu Krishna R","position":1,"cik":"0001630996","reported_name":"Polu Krishna R","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2016-10-26T16:35:51.000Z","date":"2016-10-25","kind":"disposition_to_issuer","acquired":false,"shares":23781,"price":9,"value":214029.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Agreement and Plan of Merger dated as of September 12, 2016, by and among Raptor Pharmaceutical Corp., Horizon Pharma plc, a public limited company organized under the laws of Ireland (\"Parent\") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent (the \"Merger Agreement\"), on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-16-083643","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1070698/000114036116083643/doc1.xml","form_type":"4"}}]}